BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 29435122)

  • 1. APOBEC-mediated mutagenesis in urothelial carcinoma is associated with improved survival, mutations in DNA damage response genes, and immune response.
    Glaser AP; Fantini D; Wang Y; Yu Y; Rimar KJ; Podojil JR; Miller SD; Meeks JJ
    Oncotarget; 2018 Jan; 9(4):4537-4548. PubMed ID: 29435122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. APOBEC-mediated Mutagenesis as a Likely Cause of FGFR3 S249C Mutation Over-representation in Bladder Cancer.
    Shi MJ; Meng XY; Lamy P; Banday AR; Yang J; Moreno-Vega A; Chen CL; Dyrskjøt L; Bernard-Pierrot I; Prokunina-Olsson L; Radvanyi F
    Eur Urol; 2019 Jul; 76(1):9-13. PubMed ID: 30975452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. APOBEC Mutational Signature and Tumor Mutational Burden as Predictors of Clinical Outcomes and Treatment Response in Patients With Advanced Urothelial Cancer.
    Natesan D; Zhang L; Martell HJ; Jindal T; Devine P; Stohr B; Espinosa-Mendez C; Grenert J; Van Ziffle J; Joseph N; Umetsu S; Onodera C; Turski M; Chan E; Desai A; Aggarwal R; Wong A; Porten S; Chou J; Friedlander T; Fong L; Small EJ; Sweet-Cordero A; Koshkin VS
    Front Oncol; 2022; 12():816706. PubMed ID: 35321431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of germline variants in the APOBEC3 region with cancer risk and enrichment with APOBEC-signature mutations in tumors.
    Middlebrooks CD; Banday AR; Matsuda K; Udquim KI; Onabajo OO; Paquin A; Figueroa JD; Zhu B; Koutros S; Kubo M; Shuin T; Freedman ND; Kogevinas M; Malats N; Chanock SJ; Garcia-Closas M; Silverman DT; Rothman N; Prokunina-Olsson L
    Nat Genet; 2016 Nov; 48(11):1330-1338. PubMed ID: 27643540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of new driver and passenger mutations within APOBEC-induced hotspot mutations in bladder cancer.
    Shi MJ; Meng XY; Fontugne J; Chen CL; Radvanyi F; Bernard-Pierrot I
    Genome Med; 2020 Sep; 12(1):85. PubMed ID: 32988402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of gene expression and associated mutation profiles of APOBEC3A, APOBEC3B, REV1, UNG, and FHIT with chemosensitivity of cancer cell lines to drug treatment.
    Vural S; Simon R; Krushkal J
    Hum Genomics; 2018 Apr; 12(1):20. PubMed ID: 29642934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrative genomic analysis reveals functional diversification of APOBEC gene family in breast cancer.
    Zhang Y; Delahanty R; Guo X; Zheng W; Long J
    Hum Genomics; 2015 Dec; 9():34. PubMed ID: 26682542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular analysis of urothelial cancer cell lines for modeling tumor biology and drug response.
    Nickerson ML; Witte N; Im KM; Turan S; Owens C; Misner K; Tsang SX; Cai Z; Wu S; Dean M; Costello JC; Theodorescu D
    Oncogene; 2017 Jan; 36(1):35-46. PubMed ID: 27270441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. APOBEC Mutagenesis Inhibits Breast Cancer Growth through Induction of T cell-Mediated Antitumor Immune Responses.
    DiMarco AV; Qin X; McKinney BJ; Garcia NMG; Van Alsten SC; Mendes EA; Force J; Hanks BA; Troester MA; Owzar K; Xie J; Alvarez JV
    Cancer Immunol Res; 2022 Jan; 10(1):70-86. PubMed ID: 34795033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An APOBEC3A hypermutation signature is distinguishable from the signature of background mutagenesis by APOBEC3B in human cancers.
    Chan K; Roberts SA; Klimczak LJ; Sterling JF; Saini N; Malc EP; Kim J; Kwiatkowski DJ; Fargo DC; Mieczkowski PA; Getz G; Gordenin DA
    Nat Genet; 2015 Sep; 47(9):1067-72. PubMed ID: 26258849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of APOBEC3 mutagenesis in human cancer cells.
    Petljak M; Dananberg A; Chu K; Bergstrom EN; Striepen J; von Morgen P; Chen Y; Shah H; Sale JE; Alexandrov LB; Stratton MR; Maciejowski J
    Nature; 2022 Jul; 607(7920):799-807. PubMed ID: 35859169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. APOBEC-induced mutations in human cancers are strongly enriched on the lagging DNA strand during replication.
    Seplyarskiy VB; Soldatov RA; Popadin KY; Antonarakis SE; Bazykin GA; Nikolaev SI
    Genome Res; 2016 Feb; 26(2):174-82. PubMed ID: 26755635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of a germline copy number polymorphism of APOBEC3A and APOBEC3B with burden of putative APOBEC-dependent mutations in breast cancer.
    Nik-Zainal S; Wedge DC; Alexandrov LB; Petljak M; Butler AP; Bolli N; Davies HR; Knappskog S; Martin S; Papaemmanuil E; Ramakrishna M; Shlien A; Simonic I; Xue Y; Tyler-Smith C; Campbell PJ; Stratton MR
    Nat Genet; 2014 May; 46(5):487-91. PubMed ID: 24728294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Whole-genome mapping of APOBEC mutagenesis in metastatic urothelial carcinoma identifies driver hotspot mutations and a novel mutational signature.
    Nakauma-González JA; Rijnders M; Noordsij MTW; Martens JWM; van der Veldt AAM; Lolkema MPJ; Boormans JL; van de Werken HJG
    Cell Genom; 2024 Apr; 4(4):100528. PubMed ID: 38552621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic modifiers of APOBEC-induced mutagenesis.
    Mertz TM; Rice-Reynolds E; Nguyen L; Wood A; Bray N; Mitchell D; Lobachev K; Roberts SA
    bioRxiv; 2023 Apr; ():. PubMed ID: 37066362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. APOBEC mediated mutagenesis drives genomic heterogeneity in endometriosis.
    Revathidevi S; Nakaoka H; Suda K; Fujito N; Munirajan AK; Yoshihara K; Enomoto T; Inoue I
    J Hum Genet; 2022 Jun; 67(6):323-329. PubMed ID: 35017684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular origins of APOBEC-associated mutations in cancer.
    Petljak M; Maciejowski J
    DNA Repair (Amst); 2020 Oct; 94():102905. PubMed ID: 32818816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNAs regulate APOBEC gene expression.
    Cao W; Wu W
    Histol Histopathol; 2018 Feb; 33(2):117-120. PubMed ID: 28604942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. APOBEC-mediated mutagenesis is a favorable predictor of prognosis and immunotherapy for bladder cancer patients: evidence from pan-cancer analysis and multiple databases.
    Shi R; Wang X; Wu Y; Xu B; Zhao T; Trapp C; Wang X; Unger K; Zhou C; Lu S; Buchner A; Schulz GB; Cao F; Belka C; Su C; Li M; Shu Y
    Theranostics; 2022; 12(9):4181-4199. PubMed ID: 35673559
    [No Abstract]   [Full Text] [Related]  

  • 20. Mutation Signatures Including APOBEC in Cancer Cell Lines.
    Jarvis MC; Ebrahimi D; Temiz NA; Harris RS
    JNCI Cancer Spectr; 2018 Jan; 2(1):. PubMed ID: 29888758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.